Galantamine Hydrobromide Market Report 2026

Galantamine Hydrobromide Market Overview

• Galantamine Hydrobromide market size has reached to $0.73 billion in 2025 • Expected to grow to $1.16 billion in 2030 at a compound annual growth rate (CAGR) of 9.6% • Growth Driver: Rising Prevalence Of Alzheimer’s Disease Driving The Growth Of The Market Due To Increasing Aging Population • Market Trend: Advancements in Acetylcholinesterase Inhibitors Enhancing Treatment Efficacy and Patient Adherence • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Galantamine Hydrobromide Market?

Galantamine hydrobromide is a pharmaceutical compound used to treat mild to moderate Alzheimer’s disease and other memory-related conditions. It is an acetylcholinesterase inhibitor, which increases acetylcholine levels in the brain, improving nerve signal transmission and cognitive function. Galantamine hydrobromide helps slow cognitive decline and enhance memory, attention, and overall mental function in patients with neurodegenerative disorders. The main galantamine hydrobromide products include tablet, capsule, and oral solutions. A tablet is a solid form of medicine that is taken by mouth and dissolves in the digestive system to release the active ingredients. It is applied for alzheimer's disease treatment, cognitive enhancements, and others by various end-users such as hospitals, research institutions, homecare settings, and long-term care facilities.

What Is The Galantamine Hydrobromide Market Growth Forecast?

The galantamine hydrobromide market size is expected to see strong growth in the next few years. It will grow to $1.16 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to rising prevalence of alzheimer’s disease, growing geriatric population, demand for symptom management therapies, expansion of home-based dementia care, ongoing neurodegenerative research. Major trends in the forecast period include continued use in alzheimer’s disease management, growing demand for cognitive enhancement therapies, expansion of extended-release formulations, rising adoption in geriatric care settings, increased focus on neurodegenerative disease treatment.

Global Galantamine Hydrobromide Market Segmentation

1) By Product Type: Tablet, Capsule, Oral Solution 2) By Application: Alzheimer's Disease Treatment, Cognitive Enhancements, Other Applications 3) By End-User: Hospitals, Research Institutions, Homecare Settings, Long-term Care Facilities Subsegments: 1) By Tablet: Immediate-Release Tablets, Extended-Release Tablets 2) By Capsule: Hard Gelatin Capsules, Soft Gelatin Capsules 3) By Oral Solution: Ready-to-Use Oral Solution, Concentrated Oral Solution

What Is The Driver Of The Galantamine Hydrobromide Market?

The increasing prevalence of Alzheimer's disease is expected to fuel the growth of the galantamine hydrobromide market during the forecast period. Alzheimer's disease is a progressive neurodegenerative disorder that causes memory loss, cognitive decline, and behavioral changes, often leading to an inability to perform daily tasks. The prevalence of Alzheimer's disease is increasing due to the aging population, as the risk of developing the condition significantly rises with age due to cumulative brain changes and genetic susceptibility. Galantamine Hydrobromide is required for Alzheimer's disease to boost acetylcholine levels by inhibiting its breakdown, which helps slow cognitive decline and improve memory in patients with diminishing neurotransmitter function. For instance, in August 2024, according to the Centers for Disease Control and Prevention, a US-based federal agency, the number of people living with Alzheimer's is expected to increase from 6.9 million to nearly 14 million by 2060. Therefore, the increasing prevalence of Alzheimer's disease is driving the growth of the galantamine hydrobromide industry.

Key Players In The Global Galantamine Hydrobromide Market

Major companies operating in the galantamine hydrobromide market are Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Ajinomoto Co. Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Jubilant Pharmova Limited, Cohance Lifesciences Limited, Indena S.p.A., ScinoPharm Taiwan Ltd., Estechpharma Co. Ltd.​, Nortec Química S.A., Metrochem API Private Limited, Sanochemia Pharmazeutika AG, Pellets Pharma Limited, Midas Pharma GmbH, Jubilant Generics​, Capital Farma, Wuhan Shiji Pharmaceutical Co. Ltd., Credo Life Sciences Pvt. Ltd.

Global Galantamine Hydrobromide Market Trends and Insights

Major companies operating in the galantamine hydrobromide market are focusing on developing advanced treatments, such as next-generation acetylcholinesterase inhibitors (AChEIs), to improve efficacy, reduce side effects, and enhance patient adherence. Next-generation acetylcholinesterase inhibitors (AChEIs) are advanced drugs designed to enhance cognitive function in neurodegenerative diseases by improving bioavailability and reducing side effects. For instance, in July 2024, Alpha Cognition Inc., a Canada-based biopharmaceutical company, announced the U.S. Food and Drug Administration (FDA) approval for ALPHA-1062 (Zunveyl), a prodrug of an approved acetylcholinesterase inhibitor (AChEI), galantamine, for mild to moderate Alzheimer’s disease. ALPHA-1062 stands out for its improved safety and bioavailability compared to traditional galantamine formulations. Unlike standard galantamine, it is absorbed in the small intestine as an inert drug, preventing premature binding with acetylcholinesterase (AChE) in the gastrointestinal nervous system. This is achieved by adding a benzyl ester, which minimizes local neuronal overstimulation, reduces gastrointestinal side effects, and enhances bioavailability. Once metabolized in the liver, ALPHA-1062 converts into active form, delivering galantamine to the brain through the circulatory system.

What Are Latest Mergers And Acquisitions In The Galantamine Hydrobromide Market?

In April 2024, Essential Pharma Group Limited, a UK-based specialty pharmaceutical company, acquired Reminyl (Galantamine Hydrobromide) oral capsules from Janssen Pharmaceutica NV for an undisclosed amount. This acquisition ensures continued availability and patient access to galantamine hydrobromide for Alzheimer's disease treatment. Janssen Pharmaceuticals is a Belgium-based pharmaceutical company that develops medicines for neurology, infectious diseases, immunology, oncology, and cardiology.

Regional Insights

North America was the largest region in the galantamine hydrobromide market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Galantamine Hydrobromide Market?

The galantamine hydrobromide market consists of sales of extended-release capsules, injectable solutions, transdermal patches, sublingual drops, and powder for compounding. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Galantamine Hydrobromide Market Report 2026?

The galantamine hydrobromide market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the galantamine hydrobromide industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.